DelveInsight has launched a new report on Neurofibromatosis Pipeline Insight, 2020
Neurofibromatosis Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Neurofibromatosis market. A detailed picture of the Neurofibromatosis pipeline landscape is provided, which includes the disease overview and Neurofibromatosis treatment guidelines. The assessment part of the report embraces in-depth Neurofibromatosis commercial assessment and clinical assessment of the Neurofibromatosis pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Neurofibromatosis collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
The Neurofibromatosis market report provides current treatment practices, emerging drugs, Neurofibromatosis market share of the individual therapies, current and forecasted Neurofibromatosis market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Neurofibromatosis treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Neurofibromatosis (NF) is a rare genetic disorder that causes typically benign tumors of the nerves and growths in other parts of the body. Some people with this disorder have barely noticeable neurological problems, while others are affected profoundly. NF has been classified into three distinct types; NF1, NF2 and schwannomatosis.
Request for :- Free sample page
Neurofibromatosis of pipeline development activities
The report provides insights into:
- All of the companies that are developing therapies for the treatment of Neurofibromatosis with aggregate therapies developed by each company for the same.
- Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Neurofibromatosis treatment.
- Neurofibromatosis key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Neurofibromatosis market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university web sites and industry-specific third-party sources, etc.
Neurofibromatosis Analytical Perspective by DelveInsight
- In-depth Neurofibromatosis Commercial Assessment of products
This report provides a comprehensive commercial assessment of therapeutic drugs that have been included, which comprises of collaborations, licensing, and acquisition deal value trends. The report also covers company-company collaborations (licensing/partnering), company-academia collaborations, and acquisition analysis in both graphical and tabulated form in a detailed manner.
- Neurofibromatosis Clinical Assessment of products
The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.
Scope of the report
- The Neurofibromatosis report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Neurofibromatosis across the complete product development cycle, including all clinical and nonclinical stages.
- It comprises of detailed profiles of Neurofibromatosis therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
- Detailed Neurofibromatosis research and development progress and trial details, results wherever available, are also included in the pipeline study.
- Coverage of dormant and discontinued pipeline projects along with the reasons if available across Neurofibromatosis.
Report Key facts:-
1. As per National Organization for Rare Disorders, NF1 is a rare disorder that affects males and females in equal numbers. NF1 affects all races and ethnic groups equally and is estimated to occur in 1 in 2,500 to 3,000 births.
2. According to the national institute of neurological disorder and stroke, NF1 is the most common neurofibromatosis, occurring in 1 in 3,000 to 4,000 individuals in the United States. Although many affected people inherit the disorder, between 30 and 50 percent of new cases result from a spontaneous genetic mutation of unknown cause. Once this mutation has taken place, the mutant gene can be passed to succeeding generations.
Key companies are working on disease that are given below:-
1. AstraZeneca Pharma Co
2. Array Biopharma Co.
3. Springworks Therapeutics Co.
Name of drugs covered that are given below:-
1. Report Introduction
3. Neurofibromatosis Current Treatment Patterns
3.1. Neurofibromatosis Treatment Guidelines
4. Neurofibromatosis – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Neurofibromatosis Late Stage Products (Phase-III)
7. Neurofibromatosis Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Neurofibromatosis Discontinued Products
13. Neurofibromatosis Product Profiles
14. Neurofibromatosis Key Companies
15. Neurofibromatosis Key Products
16. Dormant and Discontinued Products
16.1. Dormant Products
16.1.1. Reasons for being dormant
16.2. Discontinued Products
16.2.1. Reasons for the discontinuation
17. Neurofibromatosis Unmet Needs
18. Neurofibromatosis Future Perspectives
19. Neurofibromatosis Analyst Review
21. Report Methodology
21.1. Secondary Research
21.2. Expert Panel Validation
22. About Delveinsight
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Address:304 S. Jones Blvd #2432
State: New York
Country: United States